

## Accreditation and Designation Statements and Disclosure Report

### FSDH Masterclass

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and the FSDH Society. PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians.

PeerPoint Medical Education Institute designates the enduring format for this educational activity for a maximum of 4.25 *AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Enduring activity dates: September 30, 2022 – September 30, 2023

#### Financial Disclosures

**The following planners, speakers, reviewers or staff have relevant financial relationships to disclose:**

*“I have at present or have had within the last 24 months, a financial relationship with one or more ineligible companies.”*

Full Legal Name	Commercial Interest	For what role?
Jacinda Sampson	Dyne therapeutics	Scientific advisory board for DM1 studies
	Marigold Foundation (nonprofit)	Research funding of DM1 healthcare resource utilization
Jeffrey Statland	Avidity	Consulting
	Dyne Therapeutics	SAB
	Dyne Therapeutics	Stock options
	Fulcrum Therapeutics	SAB / Steering Committee
	Sarepta	Advisory Board
	Roche	Steering Committee
Alrabi Tawil	Fulcrum Therapeutics	Advisor Committee
	Arrowhead pharma	Advisory Committee
	MT Pharma	Consultant
	Roche pharma	Consultant
	Vective Bio	Consultant
	miRecule	Consultant
	Ipsen pharma	Advisory Board
	Dyne	Advisory Committee
	Avidity	Consultant

These financial relationships with ineligible companies have been mitigated by PeerPoint Medical Education Institute and FSHD Society.

**All other presenters, planners, editors, or staff report no relationships to disclose:**

*"I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies."*